Ari E. Hinkkanen

Ari E. Hinkkanen

Auto-generated profile, based on publicly available information

Ari E. Hinkkanen

Department of Biochemistry and Pharmacy, Åbo Akademi University, Turku, Finland

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2007 in Cancer Letters
Verified
Journal Article
Closed access
MVMarkus Vähä-Koskela
Markus Vähä-Koskela
JHJari E. Heikkilä
Jari E. Heikkilä
AHAri E. Hinkkanen
Ari E. Hinkkanen

23 August 2007 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
MAM. Ankelo
M. Ankelo
VKV. Kleimola
V. Kleimola
SSS. Simell
S. Simell
OSO. Simell
O. Simell
MKMikael Knip
Mikael Knip
AHA E Hinkkanen
A E Hinkkanen
Summary: Coeliac disease (CD) is an enteropathy induced in genetically susceptible individuals by gluten components, gliadin, hordein and secalin, polypeptides present in cereals such as wheat, barley and rye, respectively. Although the disease starts as intolerance to gliadins, antibodies to tissue transglutaminase (tTG) in the gut epithelium are characteristic of the disease. Whereas serum autoantibodies against tTG (tTGA) are highly specific for CD, antibodies to gliadin are less informative as they can also be detected in other enteropathies, and even in healthy individuals. However, it was shown recently that antibodies to certain gliadin peptides occur with high specificity in CD patient sera. We developed a solid phase lanthanide-based immunofluorometric assay for simultaneous detection of serum IgA and IgG antibodies to a synthetic peptide derived from gamma gliadin of wheat comprising amino acids 86–103. Three glutamine residues of this native 18-mer peptide were replaced by glutamic acids and the peptide was biotinylated. Sera from 87 individuals who had undergone duodenal biopsy and were diagnosed with CD and from 81 healthy individuals were analysed for the presence of both IgA and IgG anti-gliadin peptide antibodies. The performance of the peptide AGA assay was excellent, showing a specificity and sensitivity of 90% and 92% for IgA, and 98% and 75% for IgG, respectively. The corresponding values for conventional anti-gliadin antibody (AGA) enzyme-linked immunosorbent assay (ELISA) tests were 72% specificity and 87% sensitivity for IgA, and 64% specificity and 78% sensitivity for IgG. In a prospective study, almost all the tTGA-positive sera drawn from children who later developed CD were also positive for gliadin peptide antibodies.

7 February 2007 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
AWA. Westerlund
A. Westerlund
MAM. Ankelo
M. Ankelo
SSS. Simell
S. Simell
JIJ. Ilonen
J. Ilonen
MKMikael Knip
Mikael Knip
AHA E Hinkkanen
A E Hinkkanen
Coeliac disease (CD) is an immune-mediated enteropathy triggered by ingestion of wheat gluten and related cereals in genetically predisposed individuals. Circulating immunoglobulin A (IgA) class autoantibodies against tissue transglutaminase (IgA–TGA) are highly specific and sensitive serological markers for CD, which is ultimately confirmed by duodenal biopsy. Although CD is considered a life-long disorder, transient or fluctuating IgA–TGA seropositivity has been observed in asymptomatic individuals on a gluten-containing diet. We set out to explore possible differences in the maturation of IgA–TGA avidity between individuals progressing to CD and subjects remaining healthy despite occasional expression of autoantibodies. We developed a time-resolved fluorometric IgA–TGA assay based on human recombinant tissue transglutaminase (tTG), and further modified the method to also measure urea-dependent avidity of the autoantibodies. We measured the autoantibody titres and avidities of sequential serum samples from 10 children developing CD and 10 children presenting transient or fluctuating autoantibodies. Both the initial titres at seroconversion and peak values of transient/fluctuating IgA–TGA were significantly lower than corresponding autoantibody titres in samples drawn from individuals with progressing CD (P = 0·004 and P = 0·0002, respectively). However, there were no statistically significant differences in the initial or peak avidity index values between the two groups of children. The avidity index values increased during the follow-up period (P = 0·013 for both groups) with no significant difference in the rate of avidity maturation between children with transient/fluctuating IgA–TGA and children developing CD. According to our results, high autoantibody titres have a higher predictive value than avidity maturation of TGA-IgA in screening for CD.